TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery (TRAAP2)


University Hospital of Bordeaux

Status and phase

Phase 3


Postpartum Hemorrhage


Drug: Tranexamic Acid Injectable Solution
Drug: Sodium Chloride 0.9%

Study type


Funder types



CHUBX 2015/41

Details and patient eligibility


The aim is to assess the impact of tranexamic acid (TXA) for preventing postpartum hemorrhage (PPH) following a cesarean section (CS).

Full description

Regarding the prevention of PPH, recent randomized controlled trials (RCTs) of unclear quality have suggested that TXA may reduce blood loss and maternal morbidity, while a Cochrane Collaboration review has concluded, that "TXA (in addition to uterotonic medications) decreases postpartum blood loss and prevents PPH and blood transfusions following vaginal birth and CS in women at low risk of PPH based on studies of mixed quality. Further investigations are needed on efficacy and safety of this regimen for preventing PPH. Treatment, that is a 10-mL blinded vial of the study drug (either 1g TXA or placebo according to the randomization sequence), will be administered intravenously to the participant women during the third stage of labor of cesarean delivery. The follow-up visit will take place in the postpartum ward of the maternity unit, on D2 postpartum. This stage will include a venous blood sample to measure plasma concentrations of Hb and Ht, urea and creatinemia, prothrombin time (PT), active prothrombin time (aPTT), aspartate and alanine transaminase, total bilirubin and fibrinogen, and the completion of a self-questionnaire about satisfaction by the women, as well as the assessment of the adverse events. At 8 weeks postpartum, a self-questionnaire assessing psychological status and well-being will be sent to the women. At 12 weeks postpartum, all participants will be contacted by phone to assess the incidence of thrombotic and any other significant events.


4,574 patients




18 to 64 years old


No Healthy Volunteers

Inclusion criteria

: adult women admitted for a cesarean delivery before or during labor, at a term ≥ 34 weeks, hemoglobin level at the last blood sample >9g/dl, available blood test for Hb and Ht within one week before caesarean delivery, informed signed consent

Exclusion criteria

previous thrombotic event or preexisting pro-thrombotic disease, epileptic state or history of seizures, presence of any chronic or active cardiovascular disease outside hypertension, any chronic or active renal disease and chronic or active liver disease at risk thrombotic or hemorrhagic, autoimmune disease, sickle cell disease, placenta praevia, placenta accreta/increta/percreta, abruption placentae, eclampsia, HELLP syndrome, significant hemorrhage before cesarean section in utero fetal death, administration of low-molecular-weight heparin or antiplatelet agents during the week before delivery, planned general anesthesia, hypersensitivity to tranexamic acid or concentrated hydrochloric acid, instrumental extraction failure, multiple pregnancy with vaginal delivery of the first child, poor understanding of the French language.

Trial design

Primary purpose




Interventional model

Parallel Assignment


Double Blind

4,574 participants in 2 patient groups, including a placebo group

Tranexamic acid
Experimental group
intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
Drug: Tranexamic Acid Injectable Solution
Chloride solution
Placebo Comparator group
sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL).
Drug: Sodium Chloride 0.9%

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems